Publication

Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development

A new paper argues context of use, not NAMs-versus-animals, should govern nonclinical strategy in drug…

Danielle PillsburySeptember 9, 2026

Guide

From Models to Decisions: Building MIDD Readiness in the Era of ICH M15

Explore what ICH M15 means for Model-Informed Drug Development and learn how to build MIDD…

Rik de GreefSeptember 9, 2026

Live Events

An Introduction to Fast and Reliable Modeling with RsNLME and Agentic AI

CertaraSeptember 1, 2026

Publication

A glimpse into the future of model-informed drug discovery and development

Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…

CertaraAugust 28, 2026

Publication

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…

CertaraAugust 28, 2026

Webinar

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

Danielle PillsburyAugust 28, 2026

Case Study

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…

Danielle PillsburyAugust 28, 2026

Blog

The five drug development questions that bring sponsors to pharmacometrics

Sponsors rarely come to pharmacometrics because they need a model. They come with a development…

Rik de GreefAugust 24, 2026

Webinar

Beyond Trial and Error: Model-Informed Formulation Development in Practice

Siri Kalyan ChirumamillaAugust 24, 2026

Blog

MBMA data curation: How AI and expert meta-analysts get it right, fast

In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…

Matt Zierhut, PhD MBAAugust 14, 2026

Modeling and Simulation

Beyond NAMs versus animal models: Context of use as the governing framework for integrated nonclinical strategies in drug development

From Models to Decisions: Building MIDD Readiness in the Era of ICH M15

An Introduction to Fast and Reliable Modeling with RsNLME and Agentic AI

A glimpse into the future of model-informed drug discovery and development

Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology

The Road to First-in-Human: Model-Informed Decisions from Discovery to First Dose

De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)

The five drug development questions that bring sponsors to pharmacometrics

Beyond Trial and Error: Model-Informed Formulation Development in Practice

MBMA data curation: How AI and expert meta-analysts get it right, fast

Newsletter sign up

Quick links

Solutions

Contact